Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus PT from Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has received a consensus recommendation of “Reduce” from the four brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $17.00.

Several brokerages have recently commented on VRCA. Wall Street Zen downgraded Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. TD Cowen reaffirmed a “buy” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, January 7th. Finally, Zacks Research cut shares of Verrica Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at $5,878,000. Armistice Capital LLC grew its holdings in shares of Verrica Pharmaceuticals by 75.1% during the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after buying an additional 479,732 shares in the last quarter. Velan Capital Investment Management LP acquired a new position in Verrica Pharmaceuticals during the fourth quarter valued at $3,919,000. Boothbay Fund Management LLC acquired a new position in Verrica Pharmaceuticals during the third quarter valued at $1,210,000. Finally, Kalehua Capital Management LLC purchased a new stake in Verrica Pharmaceuticals in the 4th quarter worth about $1,959,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Stock Performance

Verrica Pharmaceuticals stock opened at $6.32 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. The firm has a market cap of $108.58 million, a price-to-earnings ratio of -4.00 and a beta of 1.42. Verrica Pharmaceuticals has a 1 year low of $3.28 and a 1 year high of $9.82. The firm’s 50 day moving average price is $5.61 and its two-hundred day moving average price is $6.00.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Wednesday, March 11th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The firm had revenue of $5.09 million during the quarter, compared to the consensus estimate of $4.52 million. On average, research analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.